Table 1 Baseline characteristics of the 3963 individuals within the first interval for FG-CV quintiles

N

3963

792

793

792

793

793

Sex (%)

53

51

52

50

54

56

0.10

Age (years)

61.6

54.2

69.3

63.5

56.6

70.4

63.4

56.6

70.9

61.6

55

68.9

60.2

52.6

68.2

59.4

50.9

67.7

≤ 0.001

Time since diagnosis

1.1

0.9

1.2

1.1

0.9

1.2

1.1

1

1.2

1.1

0.9

1.2

1.1

0.9

1.2

1.1

0.9

1.2

≤ 0.001

BMI (kg/m²)

30.1

26.5

32.9

29.1

25.9

31.6

30

26.5

32.8

30.2

26.5

32.9

30.4

26.7

33.5

30.8

26.7

33.8

≤ 0.001

HbA1c (%)

6.7

6

7

6.3

5.9

6.6

6.4

6

6.7

6.6

6.1

6.9

6.8

6.1

7.2

7.6

6.4

8.3

≤ 0.001

HbA1c (mmol/mol)

50.0

42.5

53

45.2

41

48.6

46.3

42

49.7

48.3

43

51.9

50.8

43.2

55

59.3

46

67.2

≤ 0.001

Glucose (mmol/L)

7.8

6.7

8.4

7.1

6.4

7.6

7.4

6.6

8.1

7.6

6.7

8.2

7.8

6.8

8.7

8.9

7

10.2

≤ 0.001

HDL (mmol/L)

1.2

1

1.4

1.3

1.1

1.5

1.3

1

1.5

1.2

1

1.4

1.2

1

1.4

1.2

1

1.3

≤ 0.001

LDL (mmol/L)

3.0

2.2

3.6

2.9

2.2

3.6

3

2.2

3.6

3

2.2

3.6

3

2.2

3.6

3

2.3

3.6

0.39

Triaglycerol (mmol/L)

1.9

1.2

2.2

1.7

1.1

2

1.8

1.2

2.1

1.9

1.2

2.2

1.9

1.2

2.3

2.2

1.3

2.5

≤ 0.001

SBP (mmHg)

141.7

128

154

141.7

128

153

143.5

130

156

142.2

128

154

140.8

126.2

153

140.2

127

152

0.01

DBP (mmHg)

80.1

73

86

79.7

73

85

79.7

73

86

79.9

73

87

80.7

74

87

80.7

74

88

≤ 0.01

Metformin (%)

54

48

53

52

58

58

0.01

Sulfonylureas (%)

25

14

18

20

31

42

≤ 0.001

Insulin (%)

5

2

2

3

5

12

≤ 0.001

Other glucose lowering drugs (%)

2

1

2

1

2

2

0.26

ACE

50.1

50.4

52.8

49.1

51.3

50.4

0.65

ARB

73.9

75.0

74.1

75.4

74.7

70.2

0.13

Smoking,  % yes

19.9

16.2

16.0

19.7

21.6

26.0

≤ 0.001

% no

67.1

68.9

68.6

67.3

66.3

64.1

% former

10.8

12.1

13.0

10.6

10.6

7.8

% unknown

2.2

2.8

2.4

2.4

1.5

2.1

European descent (%)

90.4

92.9

91.4

89.7

90.3

87.9

0.09